How a researcher uses Codex and ChatGPT to search for new antimicrobial molecules

Artificial intelligence is transforming biomedical research with applications that extend far beyond traditional use cases. César de la Fuente's laboratory has pioneered an innovative approach using OpenAI's Codex and ChatGPT to accelerate the discovery of antimicrobial molecules, offering a promising new strategy to combat the escalating global crisis of drug-resistant infections. By leveraging advanced language models to analyze both living and extinct genomes, researchers are dramatically reducing the time and resources required to identify promising antimicrobial candidates.

De la Fuente's team employs Codex, a powerful code-generating AI system, to process and interpret complex genomic sequences at unprecedented speeds. The researchers also utilize ChatGPT to enhance their search methodology, asking the AI to help identify patterns within genetic databases that might contain antimicrobial properties. This dual-AI approach enables the laboratory to scan vast genomic repositories—including genetic material from extinct organisms—searching for novel molecules capable of combating resistant bacteria, fungi, and other pathogens. The combination of computational power and pattern recognition accelerates hypothesis generation and significantly streamlines the traditional drug discovery pipeline.

• AI systems can analyze millions of genomic sequences in fraction of time required by conventional methods
• Discovery process now includes extinct organism genomes, expanding the pool of potential antimicrobial sources
• ChatGPT and Codex integration reduces manual data interpretation and accelerates research velocity
• Approach addresses critical need for novel antimicrobials against drug-resistant pathogens
• Method demonstrates practical application of generative AI in solving real-world biomedical challenges

The emergence of antimicrobial resistance represents one of modern medicine's most pressing threats, with the World Health Organization warning that drug-resistant infections could cause millions of deaths annually. Traditional antimicrobial discovery is expensive, time-consuming, and increasingly unable to keep pace with pathogen evolution. De la Fuente's work exemplifies how artificial intelligence can democratize and accelerate biomedical research, potentially bringing novel treatments to patients faster. As this methodology develops and becomes more refined, it could establish a new standard for how researchers approach infectious disease challenges, ultimately strengthening humanity's defense against resistant infections.